Johnson & Johnson (JNJ) Tops Q2 EPS by 10c, Beats on Revenue; Offers FY24 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
RBC Capital Reiterates Outperform Rating on Johnson & Johnson (JNJ)
July 18, 2024 6:14 AM EDTRBC Capital analyst Shagun Singh reiterated an Outperform rating and $175.00 price target on Johnson & Johnson (NYSE: JNJ).
The analyst comments "JNJ's stock traded higher (+3.7%) post-Q2'24 beat. It maintained its FY24 adjusted operational sales growth outlook but lowered adjusted EPS to reflect M&A-related... More
Johnson & Johnson (JNJ) PT Raised to $160 at Stifel
July 17, 2024 1:58 PM EDTStifel analyst Rick Wise raised the price target on Johnson & Johnson (NYSE: JNJ) to $160.00 (from $155.00) while maintaining a Hold rating.
The analyst comments "Offsetting concerns about China and competitive pressures, JNJs robust Innovative Medicine (65.5% of sales, +8.8% y/y) performance reiterated a still-positive 2H24 growth... More
Johnson & Johnson (JNJ) gains as Q2 earnings, revenue beat estimates
July 17, 2024 6:39 AM EDTJohnson & Johnson (NYSE: JNJ) reported a robust second quarter, with both earnings and revenue surpassing Wall Street estimates.
The healthcare giant posted adjusted earnings per share (EPS) of $2.82, exceeding analyst predictions by $0.10, and a revenue of $22.45 billion, also topping the consensus estimate of $22.34 billion.
This performance represents a 4.3% increase in reported sales growth, with an operational growth of 6.6%.
The company's stock responded positively to the news, with shares rising 2.1% as investors reacted favorably... More
